News & Updates

The American Gastroenterological Association (AGA), in an update to its living practice guideline, recommends the early use of advanced therapies for the pharmacological management of moderate-to-severe ulcerative colitis (UC) in adult outpatients.

The evidence supporting an upfront daratumumab-containing regimen as the SoC for AL amyloidosis is reaffirmed by the significant OS benefit demonstrated in the final analysis of ANDROMEDA

Treatment with proton pump inhibitors (PPIs) may contribute to a higher incidence of intestinal Behçet Disease (BD) in patients with BD, suggest the results of a study.

People living with HIV who have no history of hepatitis B virus (HBV) infection or documented response to vaccination appear to have a stronger immune response to the hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG) than that with an aluminum hydroxide adjuvant (HepB-alum).

The orally available and systemically acting small molecule modulator of sirtuin 6 (SIRT6) IMU-856 for coeliac disease demonstrates clinical activity with favourable safety profile, according to data from a phase 1 trial.

Among patients with primary biliary cholangitis (PBC), treatment with elafibranor improved predicted transplant-free survival rates based on improvements in GLOBE and UK-PBC scores, according to the phase III ELATIVE trial presented at The Liver Meeting 2024.